PROSTATE SCREENING QUALITY OF LIFE REDUCTIONS
This article was originally published in The Gray Sheet
PROSTATE SCREENING QUALITY OF LIFE REDUCTIONS outweigh the 1-2 day increases in life expectancy realized through screening, Murray Krahn, MD, University of Toronto, et al., conclude in a study published in the Sept. 14 issue of the Journal of the American Medical Association. Using information obtained from existing databases, the authors say their "analysis shows that screening may marginally reduce prostatic cancer mortality for men between the ages of 50 and 70 years, but it suggests that the benefits of reduced prostatic cancer mortality are more than offset by the morbidity of prostatic cancer treatment."
You may also be interested in...
Diagnostics company Bodysphere had to retract an announcement that it had received an emergency use authorization from the US FDA for a COVID-19 serologic test. See why Bethany Hills, an attorney with law firm Morrison & Foerster, says this may be a cautionary tale for other manufacturers.
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Japanese ICT giant applies novel advanced computing techniques with a US venture partner to more rapidly identify lead molecules from a huge virtual space.